ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Allergan Acquires Chin Fat Drug Firm

by Rick Mullin
June 22, 2015 | APPEARED IN VOLUME 93, ISSUE 25

Allergan has agreed to acquire Kythera in a cash and equity deal valued at approximately $2.1 billion. Allergan is the drug firm formerly called Actavis. Known for Botox, it will add Kythera’s newly approved Kybella (deoxycholic acid), an injectable drug providing nonsurgical treatment for submental fullness, better known as double chin. “The acquisition of Kythera is a strategic investment that strengthens our leading global position in aesthetics,” says Allergan CEO Brent Saunders. Kythera also has a drug for male-pattern baldness in early-stage development.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment